Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H
Department of Immunology, John Radcliffe Hospital, Oxford, England.
Blood. 1989 Feb;73(2):366-8.
A randomized crossover study of prophylactic immunoglobulin (IgG) therapy was performed in patients with chronic lymphocytic leukaemia (CLL) or non-Hodgkin's lymphoma (NHL). Twelve patients with hypogammaglobulinemia or a history of recurrent infections received infusions of IgG or placebo intravenously (IV) every 3 weeks for 1 year. They were then switched to the alternative preparation for another year. The number of serious bacterial infections was significantly less (P = .001; Mainland's cross-over method) in the months in which patients received IgG. Serious bacterial infections showed a trend to be associated with an IgG level less than 6.4 g/L (P = .046; Fisher's exact test).
对慢性淋巴细胞白血病（CLL）或非霍奇金淋巴瘤（NHL）患者进行了预防性免疫球蛋白（IgG）治疗的随机交叉研究。12例低丙种球蛋白血症或有反复感染病史的患者每3周静脉注射（IV）IgG或安慰剂，持续1年。然后他们改用另一种制剂再治疗1年。在患者接受IgG的月份中，严重细菌感染的数量显著减少（P = .001；Mainland交叉法）。严重细菌感染显示出与IgG水平低于6.4 g/L相关的趋势（P = .046；Fisher精确检验）。
